Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
How Parkinson’s affects million – and why current treatments are not enoughContinuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s careSerina’s drug candidate SER-252 is designed...
-
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a...
-
Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025 Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative...
-
- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”)...
-
HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for...
-
On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform...
-
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
-
HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
-
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
-
HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...